Race Oncology Ltd (RAC:ASX)

$3.86

right-arrow Created with Sketch. -0.03 (-0.77%)
MCAP $553.7M
Last trade 16.10pm 11/06/2021 20mins delayed

Latest Announcements

08/06/2021 Price SensitivePSRACRace Oncology Ltd
02/06/2021 Price SensitivePSRACRace Oncology Ltd
20/05/2021RACRace Oncology Ltd
19/05/2021RACRace Oncology Ltd
19/05/2021RACRace Oncology Ltd
19/05/2021RACRace Oncology Ltd
19/05/2021RACRace Oncology Ltd
19/05/2021RACRace Oncology Ltd

Company Overview

Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.

RAC in the news

Search Previous Announcements